Respiratory Disorders Market in United States, Forecast to 2022

Respiratory Disorders Market in United States, Forecast to 2022

Huge Gaps and Unmet Needs Across the Care Continuum Provide Opportunities for Companies to Realize Market Potential

RELEASE DATE
27-Dec-2019
REGION
North America
Research Code: ME0E-01-00-00-00
SKU: HC03253-NA-MR_23950

$3,000.00

Special Price $2,250.00 save 25 %

In stock
SKU
HC03253-NA-MR_23950

$3,000.00

$2,250.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Global resource constraints on health systems are driving a shift to value-based healthcare to reduce cost, increase access, and improve outcomes. In the United States, resource constraints affect more than 20% of the population. The number of respiratory therapists is declining at a rate of 4% to 7%, while the demand for respiratory specialists will increase by 35% by 2020. The role of respiratory therapists is critical in keeping patients out of emergency or hospital care. In the United States, nearly 15% of all primary care visits, or more than 125 million patient visits alone, are for respiratory related conditions. Within respiratory diseases, 4 conditions primarily contribute to the high burden of respiratory disease. These include asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infections (RTI), and lung cancer. More than 100 million people are affected by respiratory disease in the United States, which highlights the staggering magnitude of the burden of respiratory /lung disease. The demand-supply gap for resources is expected to widen further with the increase in incidence rates of respiratory diseases.

Though respiratory disease is one of the leading causes of morbidity and mortality among non-communicable diseases, most major respiratory conditions are preventable. Much of the respiratory conditions can be mitigated by improved screening and early diagnosis of patients/public, especially in the smoking population. Government agencies and respiratory associations are strategizing measures to reduce the burden of respiratory and sleep related disorders to have a profound effect on the respiratory health for patients, reduce economic costs, and improve the quality of life for people. Screening/diagnosis and monitoring account for only 16% of the total spending on respiratory care. A major portion, or more than 60%, of the healthcare spending is still in treatment. Investment trends show that patient medication adherence and monitoring remains the most attractive domain within respiratory care. However, little emphasis was laid on diagnosis/screening, which remains one of the primary unmet needs in the respiratory care continuum. Screening and patient medication adherence remain key market growth opportunities for OEMs within the respiratory care industry.

This research service provides an overview on the unmet needs and gaps in the respiratory disease sector and provides details on investment/funding in the respiratory sector. The unique value of this study is that it provides insights, challenges, and unmet needs for 10 major respiratory and sleep apnea conditions. This research also identifies growth opportunities by care continuum and technologies within sleep and respiratory care.

Author: Sowmya Rajagopalan

Table of Contents

Current Spending on Respiratory Care in the United States

Respiratory Care Spending by Care Continuum

Investment Landscape in Sleep and Respiratory Disease Sector by Clinical Applications

Focus of OEMs in Sleep and Respiratory Disorders

Spending on Sleep and Respiratory Disorders—Summary

Trends Shaping the Sleep and Respiratory Care Industry

Sleep and Respiratory Disease Burden in the United States

Spending on Sleep and Respiratory Disorders—Summary

Overview of Lung Cancer—Disease Burden and Spending by Care Continuum

Lung Cancer—Unmet Needs and Opportunity Analysis

Scenario Analysis—Lung Cancer Screening Population Analysis

Overview of COPD—Disease Burden and Spending by Care Continuum

COPD—Unmet Needs and Opportunity Analysis

Scenario Analysis—COPD Medication Adherence Analysis

Overview of Cystic Fibrosis—Disease Burden and Spending by Care Continuum

Cystic Fibrosis—Unmet Needs and Opportunity Analysis

Overview of Asthma—Disease Burden and Spending by Care Continuum

Asthma—Unmet Needs and Opportunity Analysis

Scenario Analysis—Asthma Medication Adherence Analysis

Overview of Pulmonary Fibrosis—Disease Burden and Spending by Care Continuum

Pulmonary Fibrosis—Unmet Needs and Opportunity Analysis

Overview of PE—Disease Burden and Spending by Care Continuum

PE—Unmet Needs and Opportunity Analysis

Scenario Analysis—PE Medication Adherence Analysis

Overview of RTI—Disease Burden and Spending by Care Continuum

RTI—Unmet Needs and Opportunity Analysis

Overview of Chronic Bronchitis—Disease Burden and Spending by Care Continuum

Chronic Bronchitis—Unmet Needs and Opportunity Analysis

Overview of Sleep Apnea—Disease Burden and Spending by Care Continuum

Sleep Apnea—Unmet Needs and Opportunity Analysis

Scenario Analysis—Sleep Apnea Treatment Adherence Analysis

Overview of Pneumonia—Disease Burden and Spending by Care Continuum

Pneumonia—Unmet Needs and Opportunity Analysis

Overview of Pleural Effusion—Disease Burden and Spending by Care Continuum

Pleural Effusion—Unmet Needs and Opportunity Analysis

Resource and Infrastructure Analysis in the United States

Programs and Long-term Plans by Respiratory Disease Types

Programs and Long-term Plans by Respiratory Disease Types (continued)

Top-level Snapshot of Funding by Care Continuum

Top-level Snapshot of Funding by Technologies

Focus of OEMs in Sleep and Respiratory Disorders

Select List of Start-up Companies

Select List of Start-up Companies (continued)

Select List of Start-up Companies (continued)

Select List of Start-up Companies (continued)

Select List of Start-up Companies (continued)

Select List of Start-up Companies (continued)

Select List of Start-up Companies (continued)

Select List of Start-up Companies (continued)

Select List of Start-up Companies (continued)

Game Changers or Start-ups Disrupting Respiratory Industry—List of Companies

Current and Recommended Business Models

Technology 1—Respiratory Airway Clearance Vest

Technology 2—Digital Capnography (Tidal Breathing CO2) Diagnostic and Monitoring Device for Home Care

Technology 3—Smartphone-enabled or Connected Spirometers

Technology 4—Continuous Respiratory Rate Monitoring

Technology 5—Implantable Nerve Stimulator for Sleep Apnea

Technology 6—Oral Appliances for Sleep Apnea

Technology 7—Miniaturized CPAP

Technology 8—Smart Inhalers/Sensors

Technology 9—Respiratory Dialysis System (ECCO₂R Therapy)

Technology 10—Breath Analyzer for Non-invasive Lung Cancer Screening

Technology 11—AI to Process Patients’ Medical Imaging

Technology 12—Patient Management Apps

Technology 13—Wearable Devices

Technology 14—Lung Perfusion System

Technology 15—Assistive Robots

Product/Technology Pipeline in Sensor-based Technologies in Respiratory and Sleep Diseases, 2018

Analysis of M&A Deals in the Global Respiratory Device Industry

Mergers and Acquisitions

Mergers and Acquisitions (continued)

Mergers and Acquisitions (continued)

Mergers and Acquisitions (continued)

Royal Philips—M&A Strategy

Apax Medical—M&A Strategy

Key M&As Discussion

Key M&As Discussion (continued)

Key M&As Discussion (continued)

Key M&As Discussion (continued)

Select Partnerships and Collaborations in Respiratory and Sleep Disorders

Select Partnerships and Collaborations in Respiratory and Sleep Disorders (continued)

Select Partnerships and Collaborations in Respiratory and Sleep Disorders (continued)

Select Partnerships and Collaborations in Respiratory and Sleep Disorders (continued)

Select Partnerships and Collaborations in Respiratory and Sleep Disorders (continued)

Leading OEMs in Respiratory Sector Continue to Ignore Screening and Early Diagnosis

Shifting Care Delivery in Sleep and Respiratory Industry

Growth Opportunity by Technologies in the Sleep and Respiratory Industry

Select Sleep and Respiratory Technologies Impact by Care Settings

Select Sleep and Respiratory Technologies Impact by Care Settings (continued)

Growth Opportunity Areas for Companies

Growth Opportunity—Collaborations and Partnerships Among Vendors

Strategic Imperatives

Future Trends in the Sleep and Respiratory Care Industry

Growth Opportunities in Sleep and Respiratory Sector by Services/Solutions

Analyst Perspective

3 Big Predictions

Strategic Imperative and Growth Opportunities for Companies

Legal Disclaimer

List of Exhibits

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
Global resource constraints on health systems are driving a shift to value-based healthcare to reduce cost, increase access, and improve outcomes. In the United States, resource constraints affect more than 20% of the population. The number of respiratory therapists is declining at a rate of 4% to 7%, while the demand for respiratory specialists will increase by 35% by 2020. The role of respiratory therapists is critical in keeping patients out of emergency or hospital care. In the United States, nearly 15% of all primary care visits, or more than 125 million patient visits alone, are for respiratory related conditions. Within respiratory diseases, 4 conditions primarily contribute to the high burden of respiratory disease. These include asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infections (RTI), and lung cancer. More than 100 million people are affected by respiratory disease in the United States, which highlights the staggering magnitude of the burden of respiratory /lung disease. The demand-supply gap for resources is expected to widen further with the increase in incidence rates of respiratory diseases. Though respiratory disease is one of the leading causes of morbidity and mortality among non-communicable diseases, most major respiratory conditions are preventable. Much of the respiratory conditions can be mitigated by improved screening and early diagnosis of patients/public, especially in the smoking population. Government agencies and respiratory associations are strategizing measures to reduce the burden of respiratory and sleep related disorders to have a profound effect on the respiratory health for patients, reduce economic costs, and improve the quality of life for people. Screening/diagnosis and monitoring account for only 16% of the total spending on respiratory care. A major portion, or more than 60%, of the healthcare spending is still in treatment. Investment trends show that patient medication adherence and monitoring remains the most attractive domain within respiratory care. However, little emphasis was laid on diagnosis/screening, which remains one of the primary unmet needs in the respiratory care continuum. Screening and patient medication adherence remain key market growth opportunities for OEMs within the respiratory care industry. This research service provides an overview on the unmet needs and gaps in the respiratory disease sector and provides details on investment/funding in the respiratory sector. The unique value of this study is that it provides insights, challenges, and unmet needs for 10 major respiratory and sleep apnea conditions. This research also identifies growth opportunities by care continuum and technologies within sleep and respiratory care. Author: Sowmya Rajagopalan
More Information
No Index No
Podcast No
Author Sowmya Rajagopalan
Industries Healthcare
WIP Number ME0E-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9A47-B1,9A4B-B1